Procter & Gamble Health Ltd Announces Q2 Results: Sales up 3%, PAT up 8% for Quarter Ended September 30, 2025
Procter & Gamble Health Ltd. (PGHL) announced its financial results for the second quarter ended September 30, 2025. The Company delivered sales of ¥319 crores, up 3% versus a year ago, driven by strong brand fundamentals and positive consumer response to new innovations. Profit After Tax (PAT) stood at ¥89 crores, up 8% versus a year ago, led by growth in sales. The growth is attributed to strategic efforts across the value chain including a strategic consumer communication initiative on Evion and Seven Seas, and the introduction of new products like the Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream among others. The company continues to strengthen its supply chain capabilities, ensuring they are addressing the evolving needs of their consumers, customers and healthcare professionals.
Key Highlights
- Sales up by 3% compared to the same period last year
- Profit After Tax (PAT) up by 8% compared to the same period last year
- Strong brand fundamentals and positive consumer response to new innovations
- Introduction of new products like Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream
- Strengthening of supply chain capabilities to address the evolving needs of consumers, customers and healthcare professionals